The only single cell sequencing platform that isolates and captures all three cancer phenotypes: Dormant, Clonogenic and Migrating | A precision oncology drug discovery platform with capacity for 3-D label-free imaging and machine learning multiomic analysis.

SingleCell Biotechnology has pioneered a functional, single-cell, label-free platform — micro-fabricated with distinct features that can isolate dormant, migratory, and clonogenic phenotypes.  Our Single Cell Intelligent Analysis Platform (SCI-AP) accommodates multiomic assays in service of more efficient drug discovery and improved patient outcomes, particularly in high-relapse and high-recurrence oncology.

In a licensing partnership with UTSW and with a robust CPRIT grant (Cancer Prevention and Research Institute of Texas), SingleCell Biotechnology is seeking investment partners to fund its clinical research and platform expansion, as well as drug discovery, academic research and CRO enterprise partnerships in the development of precision oncology therapeutics.

SingleCell Biotechnology

Org chart

Teams

Offices